{ "schemaVersion": 1, "organisationId": "O-ab897ed8e236433597cc8ac2b2fda11c", "slug": "ipsen", "name": "IPSEN", "updatedAt": "2026-10-04T14:44:18.307797Z", "sections": [ { "type": "OVERVIEW", "text": "Ipsen is a global specialty-care biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. Its portfolio includes products such as Somatuline, Cabometyx, Decapeptyl and Onivyde in Oncology, and Iqirvo, Bylvay and Sohonos in Rare Disease. [P80905516][P42201877][P83157648][P47283528] Ipsen describes its mission as prolonging and improving lives and health outcomes while making a positive impact on society. [https://www.ipsen.com/company/]\n\nFounded in 1929, Ipsen reported 2025 total sales of €3,675.9 million. [https://www.ipsen.com/company/history/][T1962541] The company has more than 5,000 employees, and its products are registered in 88 countries. [https://www.ipsen.com/company/]\n[P80905516][P42201877][P83157648][P47283528][T1962541][https://www.ipsen.com/company/][https://www.ipsen.com/company/history/]", "updatedAt": "2026-10-04T14:44:18.307797Z" }, { "type": "PRODUCTS", "text": "Ipsen markets prescription medicines in oncology, rare disease and neuroscience. Its oncology portfolio includes Somatuline (lanreotide), a long-acting injectable used for neuroendocrine tumors, acromegaly and symptoms of carcinoid syndrome; Cabometyx (cabozantinib), used for several cancers, including renal-cell and hepatocellular carcinoma; Decapeptyl (triptorelin), supplied in depot formulations for indications that vary by market; and Onivyde, a liposomal irinotecan injection used in pancreatic cancer regimens. Ojemda (tovorafenib) is a targeted therapy for eligible patients with relapsed or refractory pediatric low-grade glioma and received conditional EU authorization in April 2026. [https://www.ipsen.com/press-release/ipsen-announces-investment-in-new-state-of-the-art-electronic-autoinjector-for-somatuline-autogel-somatuline-depot-lanreotide-designed-to-improve-patient-experience/][https://www.ipsen.com/product/cabometyx-cabozantinib/][https://www.ipsen.com/product/decapeptyl-triptorelin-pamoate-or-acetate/][https://www.ipsen.com/product/onivyde-irinotecan-liposome-injection/][https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/]\n\nIts rare-disease medicines include Iqirvo (elafibranor) for primary biliary cholangitis and Bylvay (odevixibat) for cholestatic pruritus associated with progressive familial intrahepatic cholestasis; Bylvay is also approved in the U.S. for Alagille syndrome. In neuroscience, Dysport (abobotulinumtoxinA) is an injectable botulinum toxin used therapeutically, including for focal spasticity, and for aesthetic indications such as facial lines; approved uses vary by country. [https://www.ipsen.com/press-release/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis/][https://www.ipsen.com/press-release/u-s-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome/][https://www.ipsen.com/singapore/products/dysport-abobotulinumtoxina/]\n\nFor FY2025, Ipsen reported sales of €3,675.9 million. Somatuline contributed €1,135.4 million (about 30.9% of total sales), Dysport €734.1 million (20.0%), Cabometyx €613.2 million (16.7%), Decapeptyl €542.9 million (14.8%), Onivyde €207.4 million (5.6%), Iqirvo €184.0 million (5.0%) and Bylvay €180.0 million (4.9%); percentages are calculated from reported sales. Dysport’s FY2025 sales comprised €436.4 million in aesthetics and €297.7 million in therapeutics. The U.S. Ipsen CARES program provides patient access and treatment support, including benefit verification and assistance for eligible patients; it is not reported as a separate product revenue line. Brand ownership or licensing arrangements may differ. [T237712][https://www.ipsen.com/us/patients/][P34241861]\n[T237712][P34241861][https://www.ipsen.com/press-release/ipsen-announces-investment-in-new-state-of-the-art-electronic-autoinjector-for-somatuline-autogel-somatuline-depot-lanreotide-designed-to-improve-patient-experience/][https://www.ipsen.com/product/cabometyx-cabozantinib/][https://www.ipsen.com/product/decapeptyl-triptorelin-pamoate-or-acetate/][https://www.ipsen.com/product/onivyde-irinotecan-liposome-injection/][https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/][https://www.ipsen.com/press-release/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis/][https://www.ipsen.com/press-release/u-s-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome/][https://www.ipsen.com/singapore/products/dysport-abobotulinumtoxina/][https://www.ipsen.com/us/patients/]", "updatedAt": "2026-10-04T14:44:18.307797Z" }, { "type": "GEOGRAPHY", "text": "In FY2025, Ipsen generated €3,675.9 million in sales: 40% in Europe (€1,461.0 million), 35% in North America (€1,290.6 million) and 25% in the Rest of the World (€924.3 million). The United States accounted for €1,210.3 million and France for €293.0 million; the reported regional definition of Europe includes the EU, UK, Iceland, Liechtenstein, Norway and Switzerland. [T8460480][https://www.ipsen.com/wp-content/uploads/2026/02/Ipsen-FY-2025-results-highlights.pdf] Ipsen reports teams in more than 40 countries and medicines reaching patients in more than 100 countries. [https://www.ipsen.com/press-release/ipsen-announces-the-availability-of-its-2025-universal-registration-document-3266870/]\n\nIts identified sites include its Paris headquarters; Dublin; Signes and Dreux in France; Wrexham in the UK; and global hubs in London and Cambridge, Massachusetts. The company describes Dublin as combining manufacturing, research and development, and commercial activity; Signes as a major production site; Dreux as a pharmaceutical development centre; and Wrexham as a Dysport production site. [https://www.ipsen.com/media-resources/locations/][https://www.ipsen.com/contact-us/location/][https://www.ipsen.com/uk-ireland/ipsen-in-ireland/][https://www.ipsen.com/france/a-propos-de-nous/][https://www.ipsen.com/france/location/dreux-pharmsciences-centre-de-developpement-pharmaceutique/][https://www.ipsen.com/annualreport/wp-content/uploads/sites/3/2026/05/Ipsen-2025-Integrated-Annual-Report.pdf] Ipsen reported 5,535 employees at year-end 2025; a regional employee breakdown was not identified for that year. Its 2024 HR KPI report stated that Europe represented 63% of employees. [T928605][https://www.ipsen.com/wp-content/uploads/2026/08/2026-HR-KPIs-report.pdf][https://www.ipsen.com/wp-content/uploads/2025/07/2025-HR-KPIs-report_VF.pdf]\n[T8460480][T928605][https://www.ipsen.com/wp-content/uploads/2026/02/Ipsen-FY-2025-results-highlights.pdf][https://www.ipsen.com/press-release/ipsen-announces-the-availability-of-its-2025-universal-registration-document-3266870/][https://www.ipsen.com/media-resources/locations/][https://www.ipsen.com/contact-us/location/][https://www.ipsen.com/uk-ireland/ipsen-in-ireland/][https://www.ipsen.com/france/a-propos-de-nous/][https://www.ipsen.com/france/location/dreux-pharmsciences-centre-de-developpement-pharmaceutique/][https://www.ipsen.com/annualreport/wp-content/uploads/sites/3/2026/05/Ipsen-2025-Integrated-Annual-Report.pdf][https://www.ipsen.com/wp-content/uploads/2026/08/2026-HR-KPIs-report.pdf][https://www.ipsen.com/wp-content/uploads/2025/07/2025-HR-KPIs-report_VF.pdf]", "updatedAt": "2026-10-04T14:44:18.307797Z" }, { "type": "SEGMENTS", "text": "Ipsen reports one IFRS 8 operating segment, Specialty Care. Its sales are also presented by therapeutic area; these are sales categories, not separate operating segments. In 2025, Oncology generated €2,545.0 million (about 69.2% of group sales), Neuroscience €746.6 million (about 20.3%), and Rare Disease €384.3 million (about 10.5%). [P80139254][T10877566]\n\nOncology includes products such as Somatuline, Cabometyx, Decapeptyl, Onivyde and Tazverik, with indications spanning neuroendocrine and renal-cell tumors, prostate cancer and metastatic pancreatic cancer. [T10877566][T5161691] Neuroscience sales were predominantly Dysport; reported uses include limb spasticity and cervical dystonia. [T10877566][P84609301][P57582187][P60325772] Rare Disease includes Bylvay, Iqirvo and Sohonos, with reported focus areas including cholestatic pruritus, primary biliary cholangitis and fibrodysplasia ossificans progressiva. [T10877566][T5377980] Ipsen also discloses sales by geography: Europe contributed about 40%, North America 35% and Rest of the World 25% in 2025; this is a geographic sales breakdown rather than an alternative operating-segment basis. [T8460480][P80139254]\n[P80139254][T10877566][T10877566][T10877566][T5161691][P84609301][P57582187][P60325772][T5377980][T8460480][T8460480][T8460480][T8460480]", "updatedAt": "2026-10-04T14:44:18.307797Z" }, { "type": "HISTORY", "text": "Founded in 1929 by Dr. Henri Beaufour in Dreux, France, Laboratoires Beaufour began with Romarène, a rosemary-derived product for digestive disorders. In 1975, the company created Ipsen as a subsidiary; it expanded its product portfolio with launches including Smecta in 1977 and Decapeptyl in 1986. [P25061186][https://www.ipsen.com/us/company/][P31150278]\n\nIpsen acquired UK-based Speywood, developer of Dysport, in 1994 and launched Somatuline in France in 1995. Its shares began trading on Euronext in 2005. [P79453093][https://www.ipsen.com/wp-content/uploads/2026/04/IPSEN-UNIVERSAL-REGISTRATION-DOCUMENT-2025-ENGLISH.pdf] In 2017, it acquired Merrimack’s global oncology assets; in 2019, it completed the acquisition of Clementia Pharmaceuticals, expanding into rare diseases. [https://www.ipsen.com/company/history/][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-clementia-pharmaceuticals/]\n\nDavid Loew became CEO in 2020. In 2022, Ipsen sold its Consumer Healthcare business to Mayoly Spindler and completed the acquisition of oncology company Epizyme; in 2023, it completed the acquisition of Albireo, further expanding its rare-disease portfolio. [https://www.ipsen.com/press-release/ipsen-appoints-david-loew-as-chief-executive-officer/][https://www.ipsen.com/wp-content/uploads/2022/07/Ipsen-H1-2022-results-announcement.pdf][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/] In 2025, it completed the acquisition of ImCheck Therapeutics, and in 2026 it announced an agreement to acquire Kartos Therapeutics. [https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-imcheck-therapeutics-expanding-oncology-pipeline-3205646/][https://www.ipsen.com/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643/]\n[P25061186][P31150278][P79453093][https://www.ipsen.com/us/company/][https://www.ipsen.com/wp-content/uploads/2026/04/IPSEN-UNIVERSAL-REGISTRATION-DOCUMENT-2025-ENGLISH.pdf][https://www.ipsen.com/company/history/][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-clementia-pharmaceuticals/][https://www.ipsen.com/press-release/ipsen-appoints-david-loew-as-chief-executive-officer/][https://www.ipsen.com/wp-content/uploads/2022/07/Ipsen-H1-2022-results-announcement.pdf][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/][https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-imcheck-therapeutics-expanding-oncology-pipeline-3205646/][https://www.ipsen.com/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643/]", "updatedAt": "2026-10-04T14:44:18.307797Z" } ], "sources": [ { "id": "P80905516", "href": "https://app.finbar.com/go?id=P80905516", "label": "IPSEN — Press release (2026 Q 1), p1", "documentId": "D-9623a86a21354182b04090ae45be32e3", "page": 1 }, { "id": "P42201877", "href": "https://app.finbar.com/go?id=P42201877", "label": "IPSEN — Full financial report (2025 Y), p48", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 48 }, { "id": "P83157648", "href": "https://app.finbar.com/go?id=P83157648", "label": "IPSEN — Press release (2026 Q 1), p3", "documentId": "D-9623a86a21354182b04090ae45be32e3", "page": 3 }, { "id": "P47283528", "href": "https://app.finbar.com/go?id=P47283528", "label": "IPSEN — Full financial report (2025 Y), p16", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 16 }, { "id": "https://www.ipsen.com/company/", "href": "https://www.ipsen.com/company/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/company/history/", "href": "https://www.ipsen.com/company/history/", "label": "www.ipsen.com" }, { "id": "T1962541", "href": "https://app.finbar.com/go?id=T1962541", "label": "IPSEN — Full financial report (2025 Y), p83", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 83 }, { "id": "https://www.ipsen.com/press-release/ipsen-announces-investment-in-new-state-of-the-art-electronic-autoinjector-for-somatuline-autogel-somatuline-depot-lanreotide-designed-to-improve-patient-experience/", "href": "https://www.ipsen.com/press-release/ipsen-announces-investment-in-new-state-of-the-art-electronic-autoinjector-for-somatuline-autogel-somatuline-depot-lanreotide-designed-to-improve-patient-experience/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/product/cabometyx-cabozantinib/", "href": "https://www.ipsen.com/product/cabometyx-cabozantinib/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/product/decapeptyl-triptorelin-pamoate-or-acetate/", "href": "https://www.ipsen.com/product/decapeptyl-triptorelin-pamoate-or-acetate/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/product/onivyde-irinotecan-liposome-injection/", "href": "https://www.ipsen.com/product/onivyde-irinotecan-liposome-injection/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/", "href": "https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis/", "href": "https://www.ipsen.com/press-release/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/u-s-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome/", "href": "https://www.ipsen.com/press-release/u-s-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/singapore/products/dysport-abobotulinumtoxina/", "href": "https://www.ipsen.com/singapore/products/dysport-abobotulinumtoxina/", "label": "www.ipsen.com" }, { "id": "T237712", "href": "https://app.finbar.com/go?id=T237712", "label": "IPSEN — Press release (2025 Y), p6", "documentId": "D-a96fa717c5d140e58ef81424a5e76ee1", "page": 6 }, { "id": "https://www.ipsen.com/us/patients/", "href": "https://www.ipsen.com/us/patients/", "label": "www.ipsen.com" }, { "id": "P34241861", "href": "https://app.finbar.com/go?id=P34241861", "label": "IPSEN — Presentation (2025 Y), p2", "documentId": "D-58b2d429661d45c2b9e117c150e9b029", "page": 2 }, { "id": "T8460480", "href": "https://app.finbar.com/go?id=T8460480", "label": "IPSEN — Full financial report (2025 Y), p102", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 102 }, { "id": "https://www.ipsen.com/wp-content/uploads/2026/02/Ipsen-FY-2025-results-highlights.pdf", "href": "https://www.ipsen.com/wp-content/uploads/2026/02/Ipsen-FY-2025-results-highlights.pdf", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-announces-the-availability-of-its-2025-universal-registration-document-3266870/", "href": "https://www.ipsen.com/press-release/ipsen-announces-the-availability-of-its-2025-universal-registration-document-3266870/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/media-resources/locations/", "href": "https://www.ipsen.com/media-resources/locations/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/contact-us/location/", "href": "https://www.ipsen.com/contact-us/location/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/uk-ireland/ipsen-in-ireland/", "href": "https://www.ipsen.com/uk-ireland/ipsen-in-ireland/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/france/a-propos-de-nous/", "href": "https://www.ipsen.com/france/a-propos-de-nous/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/france/location/dreux-pharmsciences-centre-de-developpement-pharmaceutique/", "href": "https://www.ipsen.com/france/location/dreux-pharmsciences-centre-de-developpement-pharmaceutique/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/annualreport/wp-content/uploads/sites/3/2026/05/Ipsen-2025-Integrated-Annual-Report.pdf", "href": "https://www.ipsen.com/annualreport/wp-content/uploads/sites/3/2026/05/Ipsen-2025-Integrated-Annual-Report.pdf", "label": "www.ipsen.com" }, { "id": "T928605", "href": "https://app.finbar.com/go?id=T928605", "label": "IPSEN — Full financial report (2025 Y), p297", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 297 }, { "id": "https://www.ipsen.com/wp-content/uploads/2026/08/2026-HR-KPIs-report.pdf", "href": "https://www.ipsen.com/wp-content/uploads/2026/08/2026-HR-KPIs-report.pdf", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/wp-content/uploads/2025/07/2025-HR-KPIs-report_VF.pdf", "href": "https://www.ipsen.com/wp-content/uploads/2025/07/2025-HR-KPIs-report_VF.pdf", "label": "www.ipsen.com" }, { "id": "P80139254", "href": "https://app.finbar.com/go?id=P80139254", "label": "IPSEN — Full financial report (2025 Y), p101", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 101 }, { "id": "T10877566", "href": "https://app.finbar.com/go?id=T10877566", "label": "IPSEN — Full financial report (2025 Y), p102", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 102 }, { "id": "T5161691", "href": "https://app.finbar.com/go?id=T5161691", "label": "IPSEN — Full financial report (2025 Y), p16", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 16 }, { "id": "P84609301", "href": "https://app.finbar.com/go?id=P84609301", "label": "IPSEN — Full financial report (2025 Y), p32", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 32 }, { "id": "P57582187", "href": "https://app.finbar.com/go?id=P57582187", "label": "IPSEN — Full financial report (2025 Y), p32", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 32 }, { "id": "P60325772", "href": "https://app.finbar.com/go?id=P60325772", "label": "IPSEN — Full financial report (2025 Y), p32", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 32 }, { "id": "T5377980", "href": "https://app.finbar.com/go?id=T5377980", "label": "IPSEN — Full financial report (2025 Y), p16", "documentId": "D-e5b47b90db5e44de8c6463dd75c8b39a", "page": 16 }, { "id": "P25061186", "href": "https://app.finbar.com/go?id=P25061186", "label": "IPSEN — Full financial report (2021 Y), p8", "documentId": "D-9018b29c748a4e02b57c62e68d41f13d", "page": 8 }, { "id": "https://www.ipsen.com/us/company/", "href": "https://www.ipsen.com/us/company/", "label": "www.ipsen.com" }, { "id": "P31150278", "href": "https://app.finbar.com/go?id=P31150278", "label": "IPSEN — Full financial report (2021 Y), p21", "documentId": "D-9018b29c748a4e02b57c62e68d41f13d", "page": 21 }, { "id": "P79453093", "href": "https://app.finbar.com/go?id=P79453093", "label": "IPSEN — Full financial report (2021 Y), p9", "documentId": "D-9018b29c748a4e02b57c62e68d41f13d", "page": 9 }, { "id": "https://www.ipsen.com/wp-content/uploads/2026/04/IPSEN-UNIVERSAL-REGISTRATION-DOCUMENT-2025-ENGLISH.pdf", "href": "https://www.ipsen.com/wp-content/uploads/2026/04/IPSEN-UNIVERSAL-REGISTRATION-DOCUMENT-2025-ENGLISH.pdf", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-clementia-pharmaceuticals/", "href": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-clementia-pharmaceuticals/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-appoints-david-loew-as-chief-executive-officer/", "href": "https://www.ipsen.com/press-release/ipsen-appoints-david-loew-as-chief-executive-officer/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/wp-content/uploads/2022/07/Ipsen-H1-2022-results-announcement.pdf", "href": "https://www.ipsen.com/wp-content/uploads/2022/07/Ipsen-H1-2022-results-announcement.pdf", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/", "href": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/", "href": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-imcheck-therapeutics-expanding-oncology-pipeline-3205646/", "href": "https://www.ipsen.com/press-release/ipsen-completes-acquisition-of-imcheck-therapeutics-expanding-oncology-pipeline-3205646/", "label": "www.ipsen.com" }, { "id": "https://www.ipsen.com/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643/", "href": "https://www.ipsen.com/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643/", "label": "www.ipsen.com" } ] }